INSIGHTS FOR COMPLEX THERAPIES

Navigate launch complexity with clarity

Evidence-based analysis on the two things that most often block access and execution: health-system readiness constraints and internal fragmentation across teams, decision rights, and handoffs.

Why Mind Meeting Group

Because complex therapies are won or lost in execution If you’re reading this, it probably means: You are commercializing a new therapy where adoption depends

Radiology team reviewing brain scans and MRI workflow dashboards, illustrating imaging operations and monitoring readiness.

Eisai demystifies MRI readiness risk in 16 hours

Eisai Canada used a 3-day Mind Meeting to accelerate MRI readiness for Leqembi (lecanemab)—clarifying constraints beyond funding and delivering decision-grade recommendations with full “village” support.

Bar chart comparing drug launch success rates: Medium pharma companies achieve 87% overall success and 89% specialty drug success versus large pharma's 72% and 62% respectively, showing 1.2x and 1.4x performance advantages

Want pharma launch excellence? Destroy the silos

New data reveals mid-size pharma companies achieve 89% launch success vs. just 62% for industry giants. The secret isn’t resources—it’s breaking down organizational silos that prevent cross-functional collaboration.